Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: A pilot study

Federico Lavorinia,*, Domenico Spina, Michael J. Walker, Lui Franciosi, Clive P. Page, Giovanni A. Fontana

*Corresponding author. Department of Experimental Medicine, Careggi University Hospital Largo Brambilla 2, 50134, Florence, Italy.
E-mail address: Federico.lavorini@unifi.it (F. Lavorini).

1. Introduction

Chronic cough remains a serious unmet medical need [1,2]. Cough is a nerve reflex involving the activation of vagally innervated receptors ultimately resulting in cough motor events [3]. Receptors (sensors) implicated in the cough reflex have been found on families of both thin myelinated (Aδ) and unmyelinated bronchial and pulmonary C sensory nerve fibres [4,5] Not surprisingly, therefore, local anaesthetics can inhibit coughing presumably via...
inhibition of conduction of these sensory nerve fibers [6], but they are known to interfere with other important protective reflexes such as the gag reflex [7], limiting their wider use in the clinic.

Caracainum chloride, that is structurally related to the local anaesthetic lidocaine [8], has been reported to reduce cough responses in guinea pigs and rabbits by selective inhibition of Aβ fibres when applied topically to the airways, whilst having no inhibitory effect on bronchial or pulmonary C-fibres, which were both inhibited by topical lidocaine [9]. To our knowledge, this selectivity for Aβ fibres has not been reported so far for other drug classes. However, to date no studies investigating the effect of inhaled caracainum chloride on cough responses have been reported in humans.

This pilot study, therefore, aimed to investigate the effectiveness of inhaled caracainum chloride (hereafter named VRP700) in controlling cough of patients with idiopathic interstitial pneumonia (IIP) [10]. Patients with IIPs were chosen since cough is a distressing and disabling symptom of this disease [10].

2. Methods

2.1. Study design and participants

This was a randomised, double blind, crossover, placebo controlled study performed according to an adaptive contingency design [11]. We enrolled adult, non-smoking inpatients with IIP and refractory chronic cough [12]. We excluded patients who reported <1 month respiratory tract infections, who were taking an angiotensin-converting enzyme inhibitor, or who had liver or renal dysfunction. Women breastfeeding or of childbearing age were also excluded. Written consent was obtained from each patient; the study was approved by the Ethics Committee of the Careggi Hospital (EudraCT number 2010-021350-19).

2.2. Protocol and recording procedures

After screening, each patient was examined on two separate (48–72 h) occasions (Fig. 1). On each occasion, patients randomly inhaled 1.0 mg/kg VRP700 or placebo (sodium chloride 0.9%) by means of a DeVilbissUltraNeb 3000 nebuliser set to produce 2 mL/min of aerosol. Administration continued until nebulisation occurred; a ~1.2 mL residue remained in the nebuliser cup after each nebulisation. After study completion, patients were followed for a further 12–24 h. On all occasions, the cough frequency was recorded at baseline and for 4 h after the completion of each inhalation period by means of a cough recorder (PulmoTrack® 2010 W-Holter, Karmelsonic) [13] and expressed as coughs per hour (cph). Cough-related level of discomfort was investigated by a 10-cm visual analogue scale (VAS), with the extremes indicating no discomfort (0 cm) or extreme discomfort (10 cm). Patients’ subjective response to treatments was also assessed 4 h post treatment asking the patients: “how do you feel: worse, same or better following treatment?” Similarly, physicians’ judgement (i.e. superior, same, inferior) of individual patient responses in terms of anti-tussive actions compared to baseline was also obtained. Vital signs, ECG and spirometry variables were recorded at baseline and 15, 20, 40, 60, 90, 120 min, 3 and 4 h after drugs administration. Concomitant medication changes and adverse events were reported. Blood and urine samples were collected for standard safety laboratory assessments; blood samples were also taken at baseline, at 20, 40, 60, 90, 120 min and 3, 4 h after VRP700 inhalation to calculate the maximum plasma concentration (Cmax) and time to reach Cmax (Tmax) [14].

2.3. Data analysis

The primary outcome variable was cough frequency over a 4-h assessment period measured before and after VRP700 and placebo administration; secondary outcome variables were VAS scores, patients’ subjective response and physicians’ judgement. Categorical data were expressed as percentages, whereas normal distributed data were presented as mean ± SD. For efficacy parameters, all tests for a difference between the two treatments have been two-sided and performed at the 5% significance level.

3. Results

Eight female patients (Table 1) completed the study with no significant changes in vital signs, ECG variables, spirometry, as well as in any parameters measured in blood or urine. Preliminary CT scans indicated that six patients suffered from usual interstitial pneumonia, one had non-specific interstitial lung disease, and another one had an unclassifiable IIP. No patients reported adverse events during the study. However, they consistently coughed more during the 1st or 2nd minutes of nebulisation of active drug, followed by a marked decrease in cough over the rest of nebulisation period. As the cough monitor was not started until after inhalation events during the study. However, they consistently coughed more during the 1st or 2nd minutes of nebulisation of active drug, followed by a marked decrease in cough over the rest of nebulisation period. As the cough monitor was not started until after inhalation had completed, these initial coughs have not been recorded.

In the patients as a group, Cmax for VRP700 ranged from 2.26 to 37.7 ng/mL with a Tmax of 20 min.

VRP700 significantly decreased cough frequency from 57.75 ± 15.51 cph to 13.13 ± 9.62 cph 4 h after VRP700 administration (p < 0.001, Fig. 2). With placebo, the same variable decreased from 46.06 ± 10.70 cph to 37.38 ± 19.34 cph (NS).

Fig. 1. Study flow chart. PK, pharmacokinetic; See text for details.
Comparisons of mean decreases in cough frequency with VRP 700 and placebo demonstrated a much higher reduction \((P < 0.001)\) in cough frequency with the active drug rather than with placebo (Fig. 1).

In all patients, VRP700 reduced \((P < 0.001)\) baseline VAS scores with an overall mean reduction of 5.60 ± 0.90. For the placebo treatment, in four patients the post-placebo values were lower than the pre-placebo values with an overall mean reduction of 1.8 ± 1.0 (Fig. 2). As with cough frequency, comparisons of mean changes in VAS score with VRP 700 and placebo demonstrated a significantly \((P < 0.001)\) higher reduction in VAS score with the active drug rather than with placebo (Fig. 2). Scrutiny of data (Fig. 2) indicated that in 4 patients treated with the sequence VRP700-placebo, the cough frequency values and VAS scores were smaller after placebo than after the reverse sequence.

All patients indicated that they felt better after receiving VRP700. Only 1 patient felt better after receiving placebo and one felt worse: the remaining patient reported no appreciable change; so that the difference between the 2 treatments was statistically significant \((P < 0.02\) by Chi squared). In all patients, physicians selected VRP700 as being the more effective \((P < 0.01)\) treatment in reducing the patient’s cough frequency.

4. Discussion

We have demonstrated a marked antitussive effect of nebulised VRP700 in patients with chronic cough and IIP with an overall 80% reduction in cough frequency. Patients also reported a remarkable subjective improvement, also confirmed by medical evaluation. VRP700 appears to be safe since none of the patients reported any clinically relevant side effect, notably no paraesthesia that has been reported following treatment with local anaesthetics.

One limitation of the crossover study design is the so-called carry over effect \([15]\). Indeed, four patients showed a larger reduction in cough frequency and VAS score when they received the sequence VRP700-placebo rather than the sequence placebo-VRP700, thus suggesting that prior exposure to the active drug may have enhanced the subsequent responses to placebo. However, overall, the active drug proved to be far more effective than placebo in the patients as a group, although there were insufficient samples to test for statistical significance of the sequence effect in the study population. On the other hand, the advantage of the statistical method used here \([11]\) is that it does not require an initial commitment to a large sample size, since the ultimate sample size was determined by the data generated during the study.

The reason for female patients being studied reflected that patient recruitment was consecutive, and the greater severity of the disease in females \([16]\) may have contributed.

The exact mechanism(s) underlying cough in IIP remains unclear \([17]\). For instance, more than 50% of patients with interstitial lung disease could have cough caused by other causes such as asthma, rhinitis or gastro-oesophageal reflux \([18,19]\). However, IIP may directly cause cough as inflammation is not limited to the parenchyma, and disrupted airway epithelium \([20]\) with inflammatory mediators known to provoke cough having been detected in such patients \([17,18]\). A further possible cause of cough in

### Table 1

<table>
<thead>
<tr>
<th>Pt. no.</th>
<th>Sex</th>
<th>Age (years)</th>
<th>BMI</th>
<th>FEV1 (% pred.)</th>
<th>FVC (% pred.)</th>
<th>TLC (% pred.)</th>
<th>DLCO (% pred.)</th>
<th>Main ongoing treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>75</td>
<td>27.07</td>
<td>63</td>
<td>60</td>
<td>62</td>
<td>49</td>
<td>OCS, PPI, N-ACC</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>79</td>
<td>27.00</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>OCS, PPI, N-ACC</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>75</td>
<td>30.05</td>
<td>88</td>
<td>90</td>
<td>80</td>
<td>65</td>
<td>PPI, N-ACC</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>75</td>
<td>28.00</td>
<td>70</td>
<td>64</td>
<td>99</td>
<td>70</td>
<td>OCS, PPI</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>56</td>
<td>23.15</td>
<td>88</td>
<td>91</td>
<td>61</td>
<td>32</td>
<td>OCS, PPI, Ox</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>69</td>
<td>36.10</td>
<td>81</td>
<td>76</td>
<td>61</td>
<td>32</td>
<td>OCS, PPI, Ox</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>68</td>
<td>33.01</td>
<td>80</td>
<td>82</td>
<td>77</td>
<td>60</td>
<td>OCS, PPI, Ox, N-ACC</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>71</td>
<td>29.00</td>
<td>66</td>
<td>66</td>
<td>64</td>
<td>48</td>
<td></td>
</tr>
</tbody>
</table>

Mean 71.00 28.00 76.57 75.57 72.57 54.71
SD 7.07 1.00 10.26 12.62 13.84 12.78

BMI, body mass index; DLCO, diffusing lung capacity; FEV1, forced expiratory volume at 1 s; FVC, forced vital capacity; NA, not available; N-ACC, N-Acetylcysteine; OCS, oral corticosteroids; Ox, oxygen; Pt, patient; PPI, proton pump inhibitors; pred, predicted value; TLC, total lung capacity.
patients with IIP is airway distortion secondary to interstitial fibrosis, which results in traction bronchiectasis [21]. Whilst the molecular mechanism of action of VRP700 remains incompletely understood, this is highly unlikely to be due to any local anaesthetic activity of this drug as it has a distinct electrophysiological profile from lidocaine on airway sensory nerves [9]. In addition, VRP700 inhibits the activation of airway Aδ fibres selectively [9], finding in keeping with a major role for Aδ fibres in many patients with chronic cough.

The antitussive effect of VRP700 is comparable to that recently reported using a P2X3 purinergic receptor antagonist (AF-219) in patients with refractory chronic cough [22]. However, unlike AF-219, which was associated with loss of taste in the majority of patients, VRP700 was not associated with any major side effects.

In conclusion, VRP700 may be promising and safe in patients with IIP. Whether the drug is also suitable for long-term administration and in the management of patients with intractable cough of different origin remains to be ascertained.

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. However, the authors acknowledge the kind gift of VRP 700 from Verona Pharma, London, UK.

Conflict of interest statement

MJW and LF are former employees of Verona Pharma. CPP, LF and MJW have equity in Verona Pharma and DS is a former consultant and has received grants from Verona Pharma. FL and GF declare no conflict of interest related to this work.

References